Greten, Tim
- Division of Basic Sciences - Nci (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #2,158
- Sustained Excellence
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2010 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$2.8M
Full award amounts, FY2023
Award Records
4
Records listing this PI
Award-Linked Rank
#2,158
By linked amount among FY2023 PIs
Earliest Year Loaded
2010
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Greten, Tim as a PI. Multi-PI records show the full award amount for context.
- 1ZIABC011345-14ZIAContact PIAnalysis of cancer-related immune suppressor mechanisms in mice$1.9Maward amount
- 1ZIABC011343-14ZIAContact PIClinical protocols for the treatment of gastrointestinal cancer$508.5Kaward amount
- $208.6Kaward amount
- 1ZIABC011344-14ZIAContact PIImmune suppressor mechanisms in patients with GI cancer$127.1Kaward amount
Award organization
Organizations that administered FY2023 awards listing Greten, Tim as a PI.
FY2023 award administered by Division of Basic Sciences - Nci ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2010First NIH AwardDivision of Basic Sciences - Nci
- 2010$500K Cumulative Funding
- 2011$1M Cumulative Funding
- 2011Entered Top 50% NationallyRanked #6124
- 2012$2M Cumulative Funding
- 2013Entered Top 25% NationallyRanked #4895
- 2014$5M Cumulative Funding
- 2018$10M Cumulative Funding
- 2021Entered Top 10% NationallyRanked #763
- 2021Entered Top 5% NationallyRanked #763